Shots:
- Eli Lilly has entered into a definitive agreement to acquire CrossBridge Bio, incl. its synergistic dual payload platform for the development of differentiated therapeutics
- As per the deal, Lilly will acquire CrossBridge Bio for ~$300M in cash, incl. an upfront payment & a subsequent milestone payment
- CrossBridge Bio is advancing CBB-120, a TROP2-targeting TOP1i/ATRi dual-payload ADC, for cancer treatment, with its US FDA’s IND submission expected in 2026
Ref: Businesswire | Image: CrossBridge Bio | Press Release
Related News: Eli Lilly Reports P-III (BRUIN CLL-322) Trial Data on Jaypirca Combination for CLL/SLL
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
